Promising data with TLR9 agonist CMP001 in melanoma has led to the exploration of this agent plus pembrolizumab also in the frontline R/M HNSCC setting (NCT04633278) (98). The gene discussed is TLR9; the disease is head and neck squamous cell carcinoma.